Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190497 | 1.00 | KMT2A (0.50) | KMT2AFAAHNPSR1MEN1F2 | |
| SCHEMBL4179487 | 1.00 | KMT2A (0.50) | KMT2AFAAHNPSR1MEN1F2 | |
| SCHEMBL4193435 | 0.82 | FAAH (0.43) | KMT2AFAAHMEN1EPHX2BCHE | |
| SCHEMBL4193428 | 0.82 | FAAH (0.43) | KMT2AFAAHMEN1EPHX2BCHE | |
| SCHEMBL4084898 | 0.81 | POLB (0.45) | KMT2AFAAHMEN1EPHX2TDP1 | |
| SCHEMBL4084892 | 0.81 | FAAH (0.52) | FAAHEPHX2 | |
| SCHEMBL4083294 | 0.81 | KMT2A (0.48) | KMT2AFAAHMEN1EPHX2TDP1 | |
| SCHEMBL4075591 | 0.79 | LMNA (0.51) | FAAHPKMTDP1 | |
| SCHEMBL4085306 | 0.79 | ALDH1A1 (0.49) | KMT2AFAAHMEN1CYP2C9PKM | |
| SCHEMBL4184955 | 0.78 | CNR1 (0.47) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | VERNALIS RESEARCH LIMITED. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | VERNALIS RESEARCH LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | CNR1, CNR2, GPR119 | KMT2A 1168/4885FAAH 116/4885NPSR1 75/4885 |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | CNR1, CNR2, GPR119 | KMT2A 1714/4885FAAH 216/4885NPSR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.